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Abstract
Background: Thailand has reformed its healthcare to ensure fairness and universality. Previous reports comparing
the fairness among the 3 main healthcare schemes, including the Universal Coverage Scheme (UCS), the Civil
Servant Medical Benefit Scheme (CSMBS) and the Social Health Insurance (SHI) have been published. They focused
mainly on provision of medication for cancers and human immunodeficiency virus infection. Since chronic kidney
disease (CKD) patients have a high rate of hospitalization and high risk of death, they also require special care and
need more than access to medicine. We, therefore, performed a 1-year, nationwide, evaluation on the clinical
outcomes (i.e., mortality rates and complication rates) and treatment costs for hospitalized CKD patients across the
3 main health insurance schemes.
Methods: All adult in-patient CKD medical expense forms in fiscal 2010 were analyzed. The outcomes focused on
were clinical outcomes, access to special care and equipment (especially dialysis), and expenses on CKD patients.
Factors influencing mortality rates were evaluated by multiple logistic regression.
Results: There were 128,338 CKD patients, accounting for 236,439 admissions. The CSMBS group was older on
average, had the most severe co-morbidities, and had the highest hospital charges, while the UCS group had the
highest rate of complications. The mortality rates differed among the 3 insurance schemes; the crude odds ratio (OR)
for mortality was highest in the CSMBS scheme. After adjustment for biological, economic, and geographic variables,
the UCS group had the highest risk of in-hospital death (OR 1.13;95% confidence interval (CI) 1.07–1.20; p < 0.001) while
the SHI group had lowest mortality (OR 0.87; 95% CI 0.76–0.99; p = 0.038). The circumscribed healthcare benefits and
limited access to specialists and dialysis care in the UCS may account for less favorable comparison with the CSMBS
and SHI groups.
Conclusions: Significant differences are observed in mortality rates among CKD patients from among the 3 main
healthcare schemes. Improvements in equity of care might minimize the differences.
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Background
Thailand implemented healthcare reforms in 2002 to en-
sure universal healthcare provision [1]. The 4 national
healthcare insurance schemes include: (i) the Universal
Coverage Scheme (UCS) provides free medical care for
persons without any other insurance (i.e., > 70% of the
population: the majority of farmers, low-income persons,
and the unemployed); (ii) the Civil Servant Medical
Benefit Scheme (CSMBS) provides free medical care for
government employees and their dependents; (iii) the
Social Health Insurance (SHI) scheme for private sector
employees; and, (iv) private insurance. The first 3
schemes cover > 96% of the population [2].
The level of healthcare in Thailand depends on the
particular hospital type and location. Community hospi-
tals principally provide primary care and have limited re-
sources for treating complex illnesses. Patients from the
latter are sent to general (secondary) and tertiary hospi-
tals, as appropriate. The distribution of hospitals in turn
depends on economics and geography. The central
region—where the capital is located—has the highest
gross domestic product (GDP) per capita (~158% of na-
tional GDP). By comparison, the respective proportion
of national GDP of the Northeast and North is 34 and
45% [3].
Previous reports—comparing the fairness of healthcare
provision among the 3 main healthcare schemes—were
mainly on the provision of medication for cancers and
HIV/AIDS [4–8]. To our knowledge, there has been no
report comparing the different healthcare schemes vis-à-
vis chronic diseases (i.e., chronic kidney diseases –
CKD) that require medicine, special care teams, special
medical equipment, and hospitalization.
Since CKD patients have an increased rate of
hospitalization and a high risk for death [9, 10], we eval-
uated the nationwide healthcare data of hospitalized
CKD patients in fiscal year 2010 for practice outcomes
of healthcare among the 3 main health insurance
schemes. Our particular focus was on differences in (i)
clinical outcomes, (ii) access to special care and equip-
ment (notably dialysis), and (iii) budgeting.
Methods
The data analyzed were from (i) the in-patients total
medical expense forms from the UCS fiscal year 2010
from the National Health Security Office; (ii) the in-
patient data from the CSMBS from the Comptroller
General’s Department; and, (iii) the in-patient data from
the SHI from the Social Security Office. The variables
included: sex, age, occupation, address, type of hospital,
health insurance scheme, co-morbidities, length of hos-
pital stay (days), complications, treatment, clinical out-
comes, and medical expenses (costs charged). Additional
information obtained from the Nephrology Society of
Thailand, the National Statistical Office, and the Office
of the National Economic and Social Development
Board, Office of the Prime Minister included: ratio of
nephrologists to dialysis units/regional population and
end-stage renal disease (ESRD) patients, and the reim-
bursement of renal replacement therapies among the dif-
ferent healthcare schemes.
The in-patient data were first checked for accuracy by
examining for (i) overlapping information (ii) visit dates
(iii) missing items (iv) incorrect coding and (v) the cor-
rect fiscal year. CKD patients were identified in either
the primary diagnosis (CKD-primary) or secondary diag-
nosis (CKD-secondary) as code N18 of the International
Statistical Classification of Diseases and Related Health
Problems, 10th revision (ICD-10) [11]. Hemodialysis and
peritoneal dialysis were identified as code 39.95 and
54.98, respectively (ICD-9-CM 2010 classification of pro-
cedures) [12]. The data were analyzed not only on the
basis of health insurance scheme but also on the level of
care provided (i.e., community/primary, general/second-
ary or tertiary hospital or private hospital) in order to as-
sess accessibility to appropriate care.
Outcome measures
The differences across the 3 health insurance schemes
vis-à-vis in-hospital mortality and high treatment cost
were examined. Demographic data, comorbidities and
complications were analyzed as to whether they affected
the two measures. In addition, policies involving the
CKD treatment of the three schemes, budget allocation
were explored to facilitate the explanation of the differ-
ences of the outcome measures (if any).
Statistical analysis
STATA version 14 was used for the statistical analyses.
The means ± SD or medians (25th-75th percentile) and
percentages were used to present the continuous and
categorical data, respectively. The generalized estimating
equation (GEE) and multiple logistic regression analysis
(MLRA) were performed to adjust the odds ratios for
factors influencing the (i) high cost accounting for mul-
tiple admissions within an individual and (ii) mortality
rate at individual level.
Results
Demographic data of the patients
In fiscal 2010, the population over 19 years of age num-
bered 47,966,734—or 74% of Thailand’s total population
of 64.7 million. Approximately 96% of the adult popula-
tion (46,208,964 persons) was covered by one of the 3
health insurance systems. The total number of adult in-
patients was 3,876,792 (admitted 4,863,935 times), ac-
counting for 71% of all in-patients. According to the 23
major disease groups in the ICD 10, among the
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respective causes of hospitalization and mortality, dis-
eases of the genitourinary system ranked 7th among
hospitalized patients (298,258 persons, 7.7% of all adults
in-patients and 392,498 admissions) and the 7th cause of
mortality [13].
CKD was the most common diagnosis of the genito-
urinary system. The total number of CKD patients was
128,338 (generating 236,439 admissions), and accounting
for 4.9% of all adult in-patient admissions (268 persons
or 493 visits per 100,000 adult population). Of these,
98,727 persons (185,161 admissions), 24,767 (42,348 ad-
missions) and 4844 (8930 admissions) were covered in
the UCS, CSMBS, and SHI groups, respectively.
Characteristics of hospitalized CKD patients under
different healthcare schemes
Table 1 presents the characteristics of CKD patients in
the UCS, CSMBS, and SHI schemes. The age of subjects
in the CSMBS were the oldest while those in the SHI
scheme were the youngest. Most of participants in the
UCS, CSMBS and SHI scheme were admitted in a com-
munity, tertiary and private hospital, respectively. The
patients in the CSMBS and SHI scheme comprised the
majority from the central region while those in the UCS
were from the Northeast region. Highest proportion of
CKD patients in the CSMBS group was diagnosed as
CKD-secondary. The respective proportion of ESRD
among in-patients under the SHI, CSMBS and UCS was
52.1, 31.6, and 24.2%.
Associated co-morbidities
The top 12 diseases associated with CKD patients were
hypertension (HT) (59.3%), diabetes mellitus (DM)
(45.5%), hyperlipidemia (18.8%), ischemic heart disease
(15.0%), heart failure (14.2%), sepsis (13.1%), gout
(10.9%), pneumonia (10.3%), acute kidney injury on top
CKD (8.9%), diarrhea (8.5%), respiratory failure (8.3%)
Table 1 Characteristics of CKD patients by the main three
health schemes















Age (mean ± SD) 66.55 ± 13.36 72.23 ± 11.46 46.99 ± 12.16












General hospital 23.58 24.49 16.72
Tertiary hospital 22.92 48.14 35.61












Hypertension 56.91 67.90 63.79
Diabetes mellitus 45.08 49.09 36.50




Heart failure 14.28 13.95 12.70
Gout 10.49 13.17 6.44
Sepsis 12.78 14.71 10.90
Pneumonia 9.94 12.25 8.20
Acute kidney injury 8.59 10.26 7.23
Diarrhea 8.63 8.34 7.51
Stroke 6.51 11.41 5.66





Hyperkalemia 15.95 11.56 11.50
Volume overload 12.44 8.96 14.80
Metabolic acidosis 9.20 5.04 4.81




Hemodialysis 6.97 16.64 24.15
















Note: CKD chronic kidney disease, ESRD end stage renal disease, N northern
region, NE northeastern region, C central region, S southern region, SD
standard deviation
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and stroke (7.4%). Patients in the CSMBS had the great-
est proportion of co-morbidities (Table 1).
Complications
Complications for all CKD patients comprised signifi-
cant anemia requiring blood transfusion (30.2%), hyper-
kalemia (14.9%), volume overload (11.9%), and metabolic
acidosis (8.2%). The rate of complications was highest in
the UCS (Table 1).
Dialysis treatment
CKD patients needed dialysis, accounting for 15,684
(12.2%) patients. The mode of dialysis included
hemodialysis (n = 12,175; 77.6%) and peritoneal dialysis
(n = 3509; 23.4%). The percentage of those needing
hemodialysis was greater under the SHI and CSMBS
than the UCS (Table 1). The respective proportion of
ESRD patients receiving both types of dialysis during ad-
mission under the UCS, SHI and CSMBS was 41.1, 50.5,
and 58.5%.
The characteristics of CKD patients defined as CKD-
primary or CKD-secondary and admitted in different
hospital levels are presented in the Additional file 1:
Table S1 and Additional file 2: Table S2. Subjects in the
CKD-secondary group were older, stayed in hospital lon-
ger, were more likely from the central region and were
admitted to a tertiary hospital. The CKD-secondary
group also had more co-morbidities, incurred a higher
hospital cost, and had higher mortality rate than the
CKD-primary group. In contrast, the rate of complica-
tions was higher in the CKD-primary group. Patients
treated in tertiary hospitals had more comorbidities; par-
ticularly cardiovascular disease, pneumonia, acute on
Table 2 Length of hospital stay and hospital charges for CKD patients by region, hospital level and healthcare scheme
Length of hospital stays (Days) Hospital charges (Baht)
Mean ± SD Median (25th-75th percentile) Mean ± SD Median (25th-75th percentile)
Insurance
UCS 5.14 ± 8.01 3.00 (2.00–6.00) 16,040 ± 131,052 6506 (3599–13,562)
CSMBS 9.40 ± 17.81 5.00 (3.00–10.00) 39,401 ± 113,206 12,685 (5694–31,169)
SHI 7.49 ± 11.11 4.00 (3.00–8.00) 36,053 ± 87,854 14,745 (6773–33,588)
Region
Northern 5.46 ± 7.41 3.00 (2.00–6.00) 15,626 ± 38,605 6796 (3660–14,335)
Northeast 4.56 ± 7.21 3.00 (2.00–5.00) 13,292 ± 164,746 5827 (3378–11,507)
Central 8.50 ± 15.74 5.00 (2.00–9.00) 37,717 ± 114,169 12,549 (5747–30,348)
Southern 6.61 ± 10.91 4.00 (2.00–7.00) 19,443 ± 47,700 7847 (4111–17,058)
Hospital levels
Community (All schemes) 4.02 ± 4.93 3.00 (2.00–5.00) 7683 ± 144,783 4482 (2830–7548)
- UCS 3.78 ± 4.43 3.00 (1.00–5.00) 7196 ± 154,018 4349 (2775–7196)
- CSMBS 5.85 ± 7.36 4.00 (3.00–7.00) 11,150 ± 24,473 5816 (3387–10,636)
- SHI 6.89 ± 10.35 4.00 (3.00–8.00) 19,013 ± 35,546 8594 (4922–20,042
General (All schemes) 6.56 ± 9.52 4.00 (2.00–7.00) 19,556 ± 119,149 9251 (4967–18,832)
- UCS 5.97 ± 8.77 4.00 (2.00–7.00) 17,969 ± 130,809 8807 (4808–17,531)
- CSMBS 9.08 ± 12.05 6.00 (3.00–10.00) 26,606 ± 56,668 12,179 (6162–25,407)
- SHI 6.85 ± 8.56 4.00 (3.00–8.00) 18,754 ± 45,335 7823 (4152–17,042)
Tertiary (All schemes) 8.64 ± 16.35 5.00 (2.00–9.00) 38,758 ± 102,610 14,404 (6998–32,997)
- UCS 7.21 ± 11.68 4.00 (2.00–8.00) 28,033 ± 65,349 12,043 (6312–25,825)
- CSMBS 11.71 ± 23.47 6.00 (3.00–12.00) 62,964 ± 154,866 22,389 (10,214–54,582)
- SHI 8.65 ± 12.90 5.00 (3.00–9.00) 31,367 ± 71,631 12,724 (5761–28,578)
Private (All schemes) 5.57 ± 8.85 3.00 (2.00–6.00) 43,915 ± 104,269 20,608 (9725–37,617)
- UCS 4.83 ± 7.71 2.00 (1.00–5.00) 42,401 ± 101,864 20,611 (9415–33,539)
- CSMBS 8.46 ± 13.55 5.00 (3.00–7.00) 30,826 ± 71,164 11,732 (7139–24,025)
- SHI 6.86 ± 10.40 4.00 (3.00–7.00) 46,805 ± 108,756 20,820 (10,395–44,565)
Note: CKD chronic kidney disease, UCS Universal Coverage Scheme, CSMBS Civil Servant Medical Benefit Scheme, SHI Social Health Insurance, SD
standard deviation
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Table 3 Factors influencing high hospital charges (>50,000 baht/1470 USD) among hospitalized, Thai, adult, CKD patients
Variables No. of admission
(times)








Female 126,027 8490 (6.7) 1 <0.001 1 <0.001
Male 110,412 9662 (8.8) 1.31 (1.27–1.36) 1.16 (1.12–1.20)
Age
19–30 4376 405 (9.3) 1 1
31–40 8392 715 (8.5) 0.92 (0.80–1.06) 0.24 1.03 (0.88–1.20) 0.70
41–50 22,172 1682 (7.6) 0.81 (0.72–0.92) 0.001 1.08 (0.94–1.24) 0.26
51–60 46,571 3408 (7.3) 0.77 (0.68–0.86) <0.001 1.05 (0.92–1.20) 0.49
61–70 62,672 4324 (6.9) 0.72 (0.64–0.81) <0.001 1.01 (0.89–1.16) 0.85
71–80 64,288 5065 (7.9) 0.82 (0.72–0.92) 0.001 1.02 (0.89–1.16) 0.82
> 80 27,968 2553 (9.1) 0.95 (0.84–1.07) 0.40 1.01 (0.88–1.17) 0.85
Insurance
CSMBS 42,348 6923 (16.4) 1 1
SHI 8930 1441 (16.1) 0.99 (0.93–1.06) 0.85 0.45 (0.41–0.49) <0.001
UCS 185,161 9788 (5.3) 0.29 (0.28–0.30) <0.001 0.38 (0.36–0.39) <0.001
Hospital level
Community 102,251 977 (1.0) 1 1
General 56,525 4049 (7.2) 7.54 (7.03–8.10) <0.001 3.58 (3.32–3.87) <0.001
Tertiary 66,150 10,974 (16.6) 19.36 (18.11–20.70) <0.001 7.17 (6.67–7.70) <0.001
Private 11,513 2152 (18.7) 23.09 (21.28–25.05) <0.001 13.82 (12.58–15.19) <0.001
Region
Northern 48,110 2645 (5.5) 1 1
Northeast 104,067 3703 (3.6) 0.63 (0.60–0.66) <0.001 0.74 (0.70–0.78) <0.001
Central 64,962 10,360 (16.0) 3.23 (3.08–3.39) <0.001 1.83 (1.74–1.94) <0.001
Southern 19,300 1444 (7.5) 1.36 (1.27–1.46) <0.001 1.21 (1.12–1.31) <0.001
Co–morbidities
Hypertension (yes/no) 125,565/110,874 11,037 (8.8)/7115 (6.4) 1.38 (1.34–1.42) <0.001 1.00 (0.96–1.04) 0.96
Diabetes mellitus (yes/no) 101,664/134,775 8775 (8.6)/9377 (7.0) 1.27 (1.23–1.31) <0.001 1.12 (1.08–1.17) <0.001
Hyperlipidemia (yes/no) 31,229/205,210 3449 (11.0)/14,703 (7.2) 1.51 (1.45–1.57) <0.001 1.06 (1.01–1.12) 0.016
Ischemic heart disease
(yes/no)
29,272/207,167 4406 (15.1)/13,746 (6.6) 2.42 (2.33–2.51) <0.001 1.75 (1.67–1.84) <0.001
Heart failure (yes/no) 24,915/211,524 2679 (10.8)/15,473 (7.3) 1.53 (1.46–1.60) <0.001 1.11 (1.05–1.17) <0.001
Gout (yes/no) 19,640/216,799 1407 (7.2)/16,745 (7.7) 0.92 (0.87–0.98) 0.005 0.99 (0.93–1.06) 0.76
Sepsis (yes/no) 18,528/217,911 4586 (24.8)/13,566 (6.2) 4.62 (4.44–4.79) <0.001 2.75 (2.62–2.88) <0.001
Pneumonia (yes/no) 14,732/221,707 4004 (27.2)/14,148 (6.4) 5.18 (4.98–5.40) <0.001 3.27 (3.10–3.45) <0.001
Acute renal failure
(yes/no)
12,133/224,306 3351 (27.6)/14,801 (6.6) 5.09 (4.88–5.31) <0.001 2.35 (2.23–2.48) <0.001
Diarrhea (yes/no) 12,085/224,354 774 (6.4)/17,378 (7.75) 0.82 (0.76–0.88) <0.001 0.98 (0.90–1.07) 0.69
Stroke (yes/no) 11,886/224,553 2313 (19.5)/15,839 (7.1) 2.97 (2.83–3.12) <0.001 1.82 (1.72–1.94) <0.001
Respiratory failure (yes/no) 11,347/225,092 3080 (27.1)/15,072 (6.7) 5.02 (4.80–5.25) <0.001 2.30 (2.17–2.44) <0.001
Complications
Anemia requiring blood 57,727/178,712 7442 (12.9)/10,710 (6.0) 2.38 (2.31–2.46) <0.001 2.25 (2.17–2.34) <0.001
Transfusion (yes/no)
Hyperkalemia (yes/no) 23,505/212,934 2532 (10.8)/15,620 (7.3) 1.57 (1.51–1.64) <0.001 1.17 (1.11–1.23) <0.001
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top CKD, and sepsis. By region, hospitals admitting the
greatest proportion of CKD patients were in the North
and Northeast in community hospitals. By comparison,
patients in the central region were admitted to tertiary
hospitals. Most of the private hospitals are also located
in the central region, where a significant number of pa-
tients in the SHI group were admitted.
Length of hospital stay
The longest hospital stay among CKD patients was in
the central region at tertiary hospitals under the CSMBS
(Table 2).
Factors influencing the high treatment cost of in-patient
Hospital charges for CKD patients were highest in (i)
the central region compared with other regions (ii) at
private hospitals compared with community, general and
tertiary hospitals, and (iii) covered by CSMBS compared
with UCS and SHI (Table 2). Comparing hospital
charges of the 3 health schemes with the same hospital
levels revealed that hospital charge of the SHI was sig-
nificantly highest at community hospitals while the
CSMBS was the highest at general and tertiary hospitals.
No significant differences in hospital charges between
the 3 health schemes treated at private hospitals were
observed (Table 2).
After adjustment with the factors affecting high hos-
pital charges (>50,000 baht or ~1470 USD per admis-
sion)—sex, hospital level, region, co-morbidities,
complications, and dialysis treatment—the UCS and SHI
groups had a respective 62 and 55% lower hospital
charges than the CSMBS (Table 3).
Factors associated with mortality
Table 4 presents patient characteristics. After adjustment
for age, sex, region, hospital level, hospital charge, co-
morbidities, complications, and mode of dialysis, the mul-
tiple logistic regression analysis revealed that the highest
mortality rate was for patients under the UCS while the
lowest was for those under the SHI. Patients under the
SHI and CSMBS had a respective 23.0 and 11.5% reduc-
tion of mortality rates compared to the UCS group.
Patients who received dialysis had a reduced mortality
(hemodialysis; OR 0.90, 95% CI 0.85–0.96, p = 0.002, peri-
toneal dialysis; OR 0.87, 95% CI 0.78–0.96, p = 0.006).
Other factors influencing the mortality rate included (i)
elderly age (ii) level of care (i.e., tertiary hospitals had
higher mortality rates than general and private hospitals
while community hospital had lowest rate); (iii) presence
of ESRD; (iv) co-morbidities (viz., sepsis, respiratory fail-
ure, stroke, pneumonia, acute on top CKD, ischemic heart
disease, heart failure, and DM); and (v) complications of
CKD (i.e., metabolic acidosis, hyperkalemia and volume
overload) (Table 5).
In addition to the factors associated with mortality,
health policies among the health schemes differed
(Table 6). Patients in the UCS trended to have fewer
benefits than patients in the other healthcare schemes.
Patients under the UCS were not able to choose the hos-
pitals with full-scale CKD care. They had to be referred
by a primary care hospital. The limited distribution of
nephrologists and dialysis units outside major urban
centres might be a barrier for patients under the UCS
who live mainly in the North and Northeast (Table 7).
Discussion
CKD is defined as abnormalities in the kidney structure
or function and/or a decreased glomerular filtration rate
for more than 3 months (GFR < 60 ml/min/1.73 m2)
[14]. Code N18 in the ICD-10 represents an older no-
menclature for chronic renal failure as a decrease in
GFR comparable to stage 3a-5 CKD patients (estimated
GFR < 60 ml/min/1.73 m2). Our study revealed that 45–
60% of admitted CKD patients also had hypertension
and diabetes. The co-morbidities associated with mortal-
ity and high hospital charges were sepsis, pneumonia, re-
spiratory failure followed by cardiovascular diseases and
AKI on pre-existing CKD. This finding agrees with pre-
vious studies that demonstrated the severity of CKD
increased in-hospital mortality among patients with
acute coronary syndrome [15–20], heart failure [21–23],
cardiac surgery [24], and stroke [25]. Early optimum
therapeutic interventions and appropriate medications
Table 3 Factors influencing high hospital charges (>50,000 baht/1470 USD) among hospitalized, Thai, adult, CKD patients
(Continued)
Volume overload (yes/no) 22,091/214,348 1966 (8.9)/16,186 (7.55) 1.30 (1.24–1.36) <0.001 0.99 (0.93–1.05) 0.67
Metabolic acidosis
(yes/no)
11,897/224,542 1549 (13.0)/16,603 (7.4) 1.90 (1.80–2.00) <0.001 1.11 (1.04–1.19) 0.003
Mode of dialysis
Hemodialysis 17,143/219,296 5239 (30.6)/12,913 (5.9) 6.45 (6.22–6.70) <0.001 3.14 (3.00–3.28) <0.001
Peritoneal dialysis 4584/231,855 1170 (25.5)/16,982 (7.3) 4.16 (3.89–4.46) <0.001 3.30 (3.04–3.59) <0.001
Note: CKD chronic kidney disease, UCS Universal Coverage Scheme, CSMBS Civil Servant Medical Benefit Scheme, SHI Social Health Insurance, CI
confidence interval
Anutrakulchai et al. BMC Health Services Research  (2016) 16:528 Page 6 of 11
might improve clinical outcomes and reduce the cost of
hospitalization.
After the Thai healthcare reforms were implemented in
2002, the poor indeed had wider access to medical services.
Equity of health financing, health workers and healthcare
infrastructure have been studied and an improving trend in
equity was reported [26–29]. Notwithstanding, differences
in access to hospital types persist among the 3 insurance
schemes. The population under UCS must be registered at
a community hospital near home. When necessary, there is
a line of referrals. Any patient who does not follow the re-
ferral process and attempts to go directly to a tertiary care
center will have to pay all costs by themselves. By compari-
son, under the CSMBS, a government employee can regis-
ter at any public hospital according to their preference [2]
while an employee covered by SHI must register at the
contracted public or private hospital [30]. If a referral is re-
quired, the employee must go to one of the hospitals in the
designated network. Only in an emergency may persons
covered by SHI or UCS be exempted from paying; however,
they must be transferred to their registered hospital as soon
as possible. These vagaries in regulations provide an ex-
planation as to why those on UCS go to community hospi-
tals and government employees go to tertiary care hospitals
[2]. Since the UCS group comprises a higher proportion of
low socio-economic patients, mainly located in rural region,
they experience delayed hospital accessibility. Furthermore,
our study revealed differences in clinical outcomes of hos-
pitalized CKD patients that might represent residual in-
equality that needs addressing.
Mortality rates of hospitalized CKD patients differed
among the 3 insurance schemes: the crude odd ratios re-
vealed the highest mortality under the CSMBS. Patients
admitted under the CSMBS had more severe or compli-
cated disease than the other schemes; as indicated by the
highest (i) percentage of life-threatening co-morbidities, (ii)
length of stay, and (iii) hospital charges. After adjusting for
biological and economic geographic variables, the multi-
variable analysis demonstrated that the UCS group had the
highest risk of in-hospital death while the SHI group had
the lowest mortality. The explanation may be related to the
limited health care benefits under the UCS compared to
the CSMBS and SHI. Table 6 presents a comparison of the
health policies among the 3 schemes. The CSMBS appears
Table 4 Characteristics of dead and alive hospitalized CKD
patients









Age (years; mean ± SD) 67.89 ± 14.04 66.79 ± 13.70 <0.001
Sex (male/female) 1/0.98 1/1.07 <0.001
Health scheme (%)






















CKD diagnosed as primary/
secondary (%)
21.7/78.3 24.2/75.8 <0.001
Proportion of ESRD ((%) 39.29 25.16 <0.001
Common co-morbidities (%)
Hypertension 59.54 59.26 0.52
Diabetes mellitus 49.40 45.06 <0.001
Hyperlipidemia 17.43 18.98 <0.001
Ischemic heart disease 23.10 14.04 <0.001
Heart failure 23.82 13.00 <0.001
Gout 10.12 10.94 0.003
Sepsis 44.68 9.29 <0.001
Pneumonia 28.06 8.19 <0.001
Acute kidney injury 21.61 7.33 <0.001
Diarrhea 8.30 8.56 0.31
Stroke 15.06 6.51 <0.001





Hyperkalemia 27.10 13.47 <0.001
Volume overload 20.58 10.81 <0.001
Metabolic acidosis 20.35 6.77 <0.001
Dialysis treatment (%)
Hemodialysis 18.29 8.43 <0.001
Peritoneal dialysis 5.21 2.44 <0.001
Table 4 Characteristics of dead and alive hospitalized CKD
patients (Continued)
Length of stay
(days; mean ± SD)
11.4 ± 24.8 5.8 ± 8.8 <0.001
Hospital charges
(baht; mean ± SD)
61,662 ± 164,842 18,656 ± 55,546 <0.001
Note: ESRD end stage renal disease, CKD chronic kidney disease, ESRD end
stage renal disease, UCS Universal Coverage Scheme, CSMBSCivil Servant
Medical Benefit Scheme, SHI Social Health Insurance, SD standard deviation
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Table 5 Prognostic factors influencing mortality rates among hospitalized, Thai, adult, CKD patients
Variables No. of patients
(persons)








Female 66,134 6814 (10.3) 1 1
Male 62,204 6941 (11.2) 1.09 (1.06–1.13) <0.001 1.03 (0.99–1.07) 0.17
Age
19–30 1869 189 (10.1) 1 1
31–40 4135 400 (9.7) 0.95 (0.79–1.14) 0.60 1.16 (0.95–1.42) 0.15
41–50 10,556 1127 (10.7) 1.06 (0.90–1.25) 0.47 1.28 (1.07–1.54) 0.008
51–60 23,073 2318 (10.0) 0.99 (0.85–1.16) 0.93 1.21 (1.01–1.44) 0.039
61–70 32,837 3277 (10.0) 0.99 (0.84–1.15) 0.85 1.25 (1.05–1.50) 0.013
71–80 37,727 4039 (10.7) 1.07 (0.91–1.24) 0.42 1.40 (1.18–1.68) <0.001
> 80 18,141 2405 (13.3) 1.36 (1.16–1.59) <0.001 1.82 (1.52–2.19) <0.001
Insurance
CSMBS 24,767 3080 (12.4) 1 1
UCS 98,727 10,253 (10.4) 0.82 (0.78–0.85) <0.001 1.13 (1.07–1.20) <0.001
SHI 4844 422 (8.7) 0.67 (0.60–0.75) <0.001 0.87 (0.76–0.99) 0.038
Hospital level
Community 56,151 3384 (6.0) 1 1
General 30,156 4091 (13.6) 2.45 (2.33–2.57) <0.001 1.58 (1.50–1.68) <0.001
Tertiary 36,274 5634 (15.5) 2.87 (2.74–3.00) <0.001 1.62 (1.53–1.71) <0.001
Private 5757 646 (11.2) 1.97 (1.80–2.15) <0.001 1.51 (1.35–1.68) <0.001
Hospital charges (Baht/USD)
First quartile (<5550/< 163) 32,090 701 (2.2) 1 1
Second quartile
(5550–13,271/163–390)
32,079 2028 (6.3) 3.02 (2.77–3.30) <0.001 2.08 (1.90–2.28) <0.001
Third quartile
(13,272–34,502/390–1015)
32,085 3680 (11.5) 5.80 (5.34–6.30) <0.001 2.98 (2.72–3.26) <0.001
Fourth quartile
(>34,502/> 1015)
32,084 7346 (22.9) 13.30 (12.28–14.39) <0.001 4.43 (4.03–4.88) <0.001
Onetime admission/Multiple
admission
80,764/47,574 7514 (9.3)/6241 (13.1) 1.47 (1.42–1.53) <0.001 0.64 (0.61–0.68) <0.001
CKD diagnosed as primary/
secondary
30,731/97,607 2991 (9.7)/10,764 (11.0) 1.15 (1.10–1.20) <0.001 0.95 (0.90–1.01) 0.11
ESRD (yes/no) 34,234/94,104 5405 (15.8)/8350 (8.9) 1.93 (1.86–2.00) <0.001 1.49 (1.42–1.57) <0.001
Co-morbidities
Diabetes mellitus (yes/no) 58,427/69,911 6795 (11.6)/6960 (10.0) 1.19 (1.15–1.23) <0.001 1.12 (1.08–1.17) <0.001
Ischemic heart disease
(yes/no)
19,264/109,074 3178 (16.5)/10,577 (9.7) 1.84 (1.76–1.92) <0.001 1.43 (1.35–1.51) <0.001
Heart failure (yes/no) 18,174/110,164 3277 (18.0)/10,478 (9.5) 2.09 (2.01–2.18) <0.001 1.38 (1.31–1.46) <0.001
Sepsis (yes/no) 16,792/111,546 6146 (36.6)/7609 (6.8) 7.89 (7.58–8.20) <0.001 4.28 (4.09–4.48) <0.001
Pneumonia (yes/no) 13,247/115,091 3860 (29.1)/9895 (8.6) 4.37 (4.19–4.56) <0.001 1.59 (1.51–1.68) <0.001
Acute renal failure (yes/no) 11,367/116,971 2972 (26.1)/10,783 (9.2) 3.49 (3.33–3.65) <0.001 1.44 (1.36–1.52) <0.001
Stroke (yes/no) 9527/118,811 2071 (21.7)/11,684 (9.8) 2.55 (2.42–2.68) <0.001 1.85 (1.73–1.96) <0.001
Respiratory failure (yes/no) 10,596/117,742 4707 (44.4)/9048 (7.7) 9.60 (9.19–10.03) <0.001 3.64 (3.45–3.83) <0.001
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to have better benefits than the other schemes; such as free
access to specialist care, free service without capitation,
and better chances of getting kidney replacement therapy
(either hemodialysis or CAPD) for ESRD patients. Further-
more, the ratios of population and ESRD patients per
nephrologist and dialysis unit were the best in Bangkok
and the central region: that is, the regions where a higher
proportion of patients are under either the CSMBS or SHI.
On the other hand, in the other regions where most
patients are under the UCS, poorer ratios prevail. The in-
sufficiency of medical personnel and equipment might be
the reasons for higher CKD complications and less dialysis
treatment in the UCS group. Previous studies confirmed
that remote CKD patients were less likely to receive
specialist care, to receive laboratory testing, and to get
appropriate medications, and were more likely to die or be
hospitalized compared with those living closer to a neph-
rologist [31, 32].




38,730/89,608 5916 (15.3)/7839 (8.7) 1.88 (1.81–1.95) <0.001 1.03 (0.98–1.07) 0.28
Hyperkalemia (yes/no) 19,165/109,173 3728 (19.5)/10,027 (9.2) 2.39 (2.29–2.49) <0.001 1.48 (1.40–1.55) <0.001
Volume overload (yes/no) 15,213/113,125 2,831 (18.6)/10,924 (9.7) 2.14 (2.04–2.24) <0.001 1.23 (1.16–1.31) <0.001
Metabolic acidosis (yes/no) 10,561/117,777 2,799 (26.5)/10,956 (9.3) 3.52 (3.35–3.69) <0.001 1.72 (1.62–1.82) <0.001
Mode of dialysis
Hemodialysis (yes/no) 12,175/116,163 2,516 (20.7)/11,239 (9.7) 2.43 (2.32–2.55) <0.001 0.90 (0.85–0.96) 0.002
Peritoneal dialysis (yes/no) 3,509/124,829 717 (20.4)/13,038 (10.4) 2.20 (2.02–2.39) <0.001 0.87 (0.78–0.96) 0.006
Note: CKD chronic kidney disease, ESRD end stage renal disease, UCS Universal Coverage Scheme, CSMBS Civil Servant Medical Benefit Scheme, SHI Social Health
Insurance, CI confidence interval
Table 6 Comparison the health policies on the health care providing and reimbursement among the three schemes
Issues SHI UCS CSMBS
Financial barriers to
equitable access
Acute complications occurred, the patients had access to special care without barrier by referral system.
Administrative efficiency Three health care schemes applied the same clinical practice guidelines
Patient and provider
autonomy
The patients received the care from
only the self-registry hospitals (either
private or public hospitals). Treatment
of ESRD was hemodialysis or CAPD
depended on facility of the self-
registry hospitals.
The patients received care only the
public hospitals in their casement
areas, mostly community or general
hospitals. The patients were referred
to higher facility hospital whenever
the complications occurred. CAPD
was the first treatment for ESRD
patients.
The patients freely chosen the public
or tertiary care hospital that they
preferred. Physicians had autonomy




Most of the patients worked in the
big cities in Bangkok and central
region of Thailand which had better
population/nephrologist ratio than
UCS
Most of the patients were in the rural
area that had least population/
nephrologist ratio
Most of the patient chosen to be
care in the tertiary care hospitals and




- Pre-dialysis No No Yes
- Dialysis Yes Yes Yes
Reimbursement of dialysis
for ESRD patients
- CAPD Yes Yes Yes
- Hemodyalysis Not more than 1,500 bahts (44 USD)/
session and not more than 4,500 bahts
(132USD)/week.
Hemodialysis was allowed only CAPD
was contraindication or having
complications. Not more than 1,500–
1,700 bahts (44–50 USD)/session and
not more than 3,000–3,400 bahts (88–
100 USD)/week.
As the actual expenses
Note: ESRD end stage renal disease, CAPD continuous ambulatory peritoneal dialysis, SHI Social Health Insurance, UCS Universal Coverage Scheme, CSMBS Civil
Servant Medical Benefit Scheme
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Improving CKD care might be achieved by imple-
menting policies that ensure fairness by providing a
comparable budget allocation among the healthcare
schemes. The “PD First” policy in Thailand launched
in 2008 initiated CAPD as renal replacement therapy
for ESRD patients under the UCS [33]. This policy
represents an effective strategy for correcting the in-
adequate distribution of hemodialysis machines and
insufficient numbers of nephrologists in rural areas
and to underprivileged groups.
Anemia is one of the complications seen in CKD pa-
tients, and this can be corrected by injection of erythro-
poiesis stimulating agent (ESA). ESA is relatively costly
and is only reimbursed during the pre-dialysis period
under the CSMBS scheme. Our data revealed that there
was a lower proportion of patients with anemia requir-
ing blood transfusion under the CSMBS than the UCS
or SHI groups. More intensive, high-cost medication
support by the 3 main health schemes might reduce
morbidity and hospitalization.
The strength of this study is that almost all of the
subjects were hospitalized adult, Thai, CKD patients.
The results, therefore, provide a clear overview of the
situation vis-à-vis these adult patients; however, some
limitations existed. Lack of a registered nationwide la-
boratory system means that there is no standardized
staging of CKD patients, which might influence the
clinical outcomes. The present study analyzed the ad-
ministrative claim data, therefore socio-economic status
of patients was not available. In addition, we are not
able to generate an area locator as a proxy for socio-
economic status of individual patients due to lack of
data. Insufficient data of these demand-side characteris-
tics observed at the individual level made some limita-
tions in comparison of equity among the three health
insurance schemes. The record of charges for each
group represents an average and this might not wholly
characterize the severity of individual patients nor in-
clude details of the procedures and medical instru-
ments needed for each patient. Moreover, the mortality
focused in this study was outcome at discharge which
may be different with mortality after discharge because
some patients died at home.
Conclusions
Concerning the treatment of hospitalized CKD patients,
the UCS group had the poorest healthcare benefits com-
pared to the other healthcare schemes—e.g., less budget
for hospital care (charge cost), poorer access to specialist
care, and treatment options that depended on variable
healthcare policies. These might explain the greater
mortality rate of those under the UCS compared to
those under the CSMBS or SHI. In order to improve
health outcomes among hospitalized CKD patients, new
healthcare policies are needed to improve budget alloca-
tions, accessibility to specialist care, and distribution of
resources.
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Bangkok 44,177 51,585 71 83
Central part 204,307 152,801 99 74
Northern 529,820 233,121 221 97
Northeastern 592,690 197,563 229 76
Southern 422,429 173,941 144 59
Note: ESRD end stage renal disease
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